Clinical Trial Update: Rituximab in Patients With Relapsed or Refractory TTP-HUS [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab in patients with relapsed or refractory thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Uremic Syndrome
• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Hamilton Health Sciences Corporation | Conditions: Thrombotic Thrombocytopenic Purpura, Hemolytic Uremic Syndrome | Phase 2 | Status: UNKNOWN